Dementia risk does not differ with GLP-1 RAs, DPP4is for seniors with type 2 diabetes, study finds
by Elana Gotkine edited by Sadie Harley, reviewed by Andrew Zinin For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus dipeptidyl peptidase-4 inhibitors (DPP4is), according to a study published online in the Annals of Internal Medicine. Kosuke Inoue, M.D., Ph.D., […]
